AUSSENDER



AOP Orphan Pharmaceuticals Aktiengesellschaft
Ansprechpartner: AOP
Tel.: +43 503 72 44 24
E-Mail: olena.weissenbacher@aoporphan.com
Pressefach (47)

Schlagwörter

AOP Orphan
Pharmaindustrie
Seltene Erkrankungen
Intensivmedizin
28.10.2020 - 10:55 | AOP Orphan Pharmaceuticals Aktiengesellschaft
ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi®
21.08.2020 - 15:00 | AOP Orphan Pharmaceuticals Aktiengesellschaft
Voices Against MPN Cancer: International Semi-Live Streaming on September 10, 2020
13.05.2019 - 13:45 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia
13.05.2019 - 13:30 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia
21.02.2019 - 09:55 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan gibt bekannt, dass BESREMi® (Ropeginterferon alfa-2b) europäische Marktzulassung für Polyzythämie vera erhält
20.02.2019 - 15:20 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV)
07.01.2019 - 10:45 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan and Chord announce a partnership to develop CRD1 (cladribine) for treatment of orphan autoimmune diseases
03.01.2019 - 15:00 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP ORPHAN AND CHORD ANNOUNCE A PARTNERSHIP TO DEVELOP CRD1 (CLADRIBINE) FOR TREATMENT OF ORPHAN AUTOIMMUNE DISEASES
17.12.2018 - 11:35 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
17.12.2018 - 11:20 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
17.12.2018 - 10:20 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®
03.12.2018 - 19:30 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at ASH
03.12.2018 - 19:15 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at ASH
11.06.2018 - 14:00 | AOP Orphan Pharmaceuticals AG
AOP Orphan announces progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b
11.06.2018 - 10:00 | AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan announces progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b
|
99.114 Abonnenten
|
232.412 Meldungen
|
94.056 Pressefotos
|
Folgen Sie uns auf Twitter
|
Persönlicher Kontakt